Put companies on watchlist
bonyf NV
ISIN: BE6333353298
WKN:
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

bonyf NV · ISIN: BE6333353298 · EQS - Company News (2 News)
Country: Belgium · Primary market: Belgium · EQS NID: 2015515
24 October 2024 11:48AM

PerioTabs Innovative 10-Day NitrAdine-Based Treatment to Revolutionize Oral Care


bonyf NV / Key word(s): Product Launch/Research Update
PerioTabs Innovative 10-Day NitrAdine-Based Treatment to Revolutionize Oral Care

24-Oct-2024 / 11:48 CET/CEST


PerioTabs®: Innovative 10-Day NitrAdine®-Based Treatment to Revolutionize Oral Care

Effervescent tablet offers a unique approach to treating gum and implant issues, enhancing overall oral hygiene

fncls.ssp?fn=download2_file&code_str=d2e5d28f1492f915eec3a38e451464ff

Ghent (Belgium), 24 October 2024, 6:00 a.m.; bonyf NV (Mnemonic: MLBON), the next-generation oral comfort expert, is a Euronext Paris listed company and specializes in the development, production and marketing of oral, denture, orthodontic and wound care products and a leader in dental care innovation. PerioTabs® is proud to introduce its groundbreaking 10-day treatment brushing solution based on the NitrAdine® formula. Designed to become an integral part of global oral care, this innovative product aims to enhance general oral hygiene for adults aged 18 and older.

"I am thrilled with the incredible work of our R&D team in bringing such great innovations to the field of oral care," said Jean-Pierre Bogaert, CEO of bonyf. "PerioTabs® stands apart with its unique effervescent tablet design, offering an effective and user-friendly 10-day treatment solution for gum and implant-related issues."

Key Benefits:

1. Clinically Proven Efficacy: Studies confirm that PerioTabs® helps reduce gingivitis, periodontitis, peri-mucositis, and peri-implantitis.

2. Rapid Results in Just 10 Days: A daily regimen over 10 days can significantly reduce pain, dental anxiety, gum bleeding and swelling, plaque buildup, and the likelihood of reinfection.

3. Safe and Well-Tolerated: When used alongside scaling and root planing, PerioTabs® is both effective and well-tolerated in managing chronic periodontitis.

4. High Patient Acceptance: Positive feedback indicates a high level of patient satisfaction, positioning PerioTabs® as a promising alternative to widely used solutions like chlorhexidine.

PerioTabs® meets biocompatibility standards according to the ISO 10993 series, ensuring no cytotoxic, irritant, or sensitizing effects. Its minimal and reversible side effects make it a safe choice for daily use. With practical packaging and an affordable price point, PerioTabs® offers a convenient 10-day treatment solution for maintaining oral hygiene.

About PerioTabs®:

PerioTabs® is dedicated to advancing oral health through innovative solutions. Utilizing patented formulations, we strive to provide effective and user-friendly products that enhance the well-being of individuals worldwide.

For more information, visit bonyf.com or contact president@bonyf.com.

bonyf’s strengths

  • Products with patented formulations
  • Produced in Switzerland compliant with stringent international quality regulations
  • Proven clinical efficacy
  • Commercial presence in 37 countries
  • Prospects for solid growth and rapid profitability
  • A fast-growing oral and dental care market

 

fncls.ssp?fn=download2_file&code_str=2ebf6fcabd7e32e45a81cdfc2c64b361

About bonyf

Incorporated in 1979, bonyf specialises in the development, production and selling of cutting-edge oral & dental care products. bonyf is a forward-thinking company committed to revolutionizing oral care through innovation and research. With a focus on quality and efficacy, bonyf develops cutting-edge products designed to enhance the well-being of individuals worldwide. Through its unwavering commitment to innovation and continuous improvement, bonyf makes a real difference to people suffering from dental and oral conditions. The company has its R&D facilities in Liechtenstein (in the renown dental valley), a production plant in Switzerland and distributes its product range in 37 countries worldwide. Benefiting from seven patent protected formulations and products developed in-house, bonyf expects strong future development, driven by the fast-growing oral and dental care market.

For more information about bonyf and its innovative oral care products, please visit www.bonyf.com.

 

bonyf

Jean-Pierre Bogaert

investor@bonyf.com

fncls.ssp?fn=download2_file&code_str=f8715437d1ff15ae7b29013d3d3887cb

 



Dissemination of a Financial Wire News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


Language: English
Issuer: bonyf NV
Doornzelestraat 114 D
9000 Gent
Belgium
Phone: +41 79 412 42 79
E-mail: president@bonyf.com
Internet: www.bonyf.com
ISIN: BE6333353298
EQS News ID: 2015515

 
End of Announcement - EQS News Service

2015515  24-Oct-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2015515&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - bonyf NV
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.